Ocular manifestations of endocrine disorders

References

• Sivaprasad S, Gupta B, Crosby-Nwaobi R, et al. Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective. Surv Ophthalmol 2012; 57: 347–370.
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102: 527–532.
   PubMed Web of Science ®Google Scholar
• Vujosevic S, Aldington SJ, Silva P, et al. Screening for diabetic retinopathy: new perspectives and challenges. Lancet Diabetes Endocrinol 2020; 8: 337–347.
   PubMed Web of Science ®Google Scholar
• Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early treatment diabetic retinopathy study research group. Ophthalmology 1991; 98: 766–785.
   PubMed Web of Science ®Google Scholar
• Silva PS, Horton MB, Clary D, et al. Identification of diabetic retinopathy and ungradable image rate with ultrawide field imaging in a national teleophthalmology program. Ophthalmology 2016; 123: 1360–1367.
   PubMed Web of Science ®Google Scholar
• Akil H, Karst S, Heisler M, et al. Application of optical coherence tomography angiography in diabetic retinopathy: a comprehensive review. Can J Ophthalmol 2019; 54: 519–528.
   Web of Science ®Google Scholar
• Tsai ASH, Jordan-Yu JM, Gan ATL, et al. Diabetic macular ischemia: influence of optical coherence tomography angiography parameters on changes in functional outcomes over one year. Invest Ophthalmol Vis Sci 2021; 62: 9-9.
   Google Scholar
• Chew EY, Davis MD, Danis RP, et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the action to control cardiovascular risk in diabetes (ACCORD) eye study. Ophthalmology 2014; 121: 2443–2451.
   PubMed Web of Science ®Google Scholar
• Fagan XJ, Chong EW. Fenofibrate and diabetic retinopathy. Clin Exp Ophthalmol. 2015; 43: 297–299.
   Web of Science ®Google Scholar
• Gabrielle P-H, Massin P, Kodjikian L, et al. Central retinal thickness following panretinal photocoagulation using a multispot semi-automated pattern-scanning laser to treat ischaemic diabetic retinopathy: treatment in one session compared with four monthly sessions. Acta Ophthalmol 2019; 97: e680–e687.
   Web of Science ®Google Scholar
• Bressler SB, Odia I, Glassman AR, et al. Changes in diabetic retinopathy severity when treating diabetic macular edema with ranibizumab: drcr.net protocol I 5-year report. Retina 2018; 38: 1896–1904.
   PubMed Web of Science ®Google Scholar
• Maturi RK, Glassman AR, Josic K, et al. Effect of intravitreous anti-vascular endothelial growth factor vs Sham treatment for prevention of vision-threatening complications of diabetic retinopathy: the protocol W randomized clinical trial. JAMA Ophthalmol 2021; 139: 701.
   PubMed Web of Science ®Google Scholar
• Jamali H, Eslami J, Kalashipour F, et al. Effect of panretinal photocoagulation on corneal sensation and tear function in patients with diabetic retinopathy. Retina 2021; 41: 338–344.
   Web of Science ®Google Scholar
• Gross JG, Glassman AR, Jampol LM, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. Jama 2015; 314: 2137–2146.
   PubMed Web of Science ®Google Scholar
• Hutton DW, Stein JD, Glassman AR, et al. Five-year cost-effectiveness of intravitreous ranibizumab therapy vs panretinal photocoagulation for treating proliferative diabetic retinopathy: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol 2019; 137: 1424–1432.
   PubMed Web of Science ®Google Scholar
• Arevalo JF, Lasave AF, Kozak I, et al. Preoperative bevacizumab for tractional retinal detachment in proliferative diabetic retinopathy: a prospective randomized clinical trial. Am J Ophthalmol 2019; 207: 279–287.
   PubMed Web of Science ®Google Scholar
• Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology 2015; 122: 1375–1394.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015; 372: 1193–1203.
   PubMed Web of Science ®Google Scholar
• Payne JF, Wykoff CC, Clark WL, et al. Randomized trial of treat and extend ranibizumab with and without navigated laser versus monthly dosing for diabetic macular edema: TREX-DME 2-year outcomes. Am J Ophthalmol 2019; 202: 91–99.
   PubMed Web of Science ®Google Scholar
• Hutton DW, Glassman AR, Stein JD, et al. Costs of managing diabetic macular edema with good visual acuity with aflibercept, laser or observation: DRCR retina network protocol V. Am J Ophthalmol 2021; 230: 297–302.
   Web of Science ®Google Scholar
• Iglicki M, Busch C, Zur D, et al. Dexamethasone implant for diabetic macular edema in naive compared with refractory eyes: the international retina group real-life 24-month multicenter study. The IRGREL-DEX study. Retina 2019; 39: 44–51.
   PubMed Web of Science ®Google Scholar
• Liu GT, Volpe NJ, and Galetta SL. Neuro-ophthalmology: diagnosis and management. Philadelphia: Elsevier; 2019.
   Google Scholar
• Regillo CD, Brown GC, Savino PJ, et al. Diabetic papillopathy. Patient characteristics and fundus findings. Arch Ophthalmol 1995; 113: 889–895.
   PubMedGoogle Scholar
• Kim M, Lee J-H, Lee S-J. Diabetic papillopathy with macular edema treated with intravitreal ranibizumab. Clin ophthalmol (Auckland, N.Z.) 2013; 7: 2257–2260.
   PubMedGoogle Scholar
• Yildirim M, Kilic D, Dursun ME, et al. Diabetic papillopathy treated with intravitreal ranibizumab. Int Med Case Rep J 2017; 10: 99–103.
   Web of Science ®Google Scholar
• Shazly TA, Latina MA. Neovascular glaucoma: etiology, diagnosis and prognosis. Semin Ophthalmol 2009; 24: 113–121.
   PubMed Web of Science ®Google Scholar
• Takihara Y, Inatani M, Fukushima M, et al. Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure. Am J Ophthalmol 2009; 147: 918.e911.
   Web of Science ®Google Scholar
• Nakatake S, Yoshida S, Nakao S, et al. Hyphema is a risk factor for failure of trabeculectomy in neovascular glaucoma: a retrospective analysis. BMC Ophthalmol 2014; 14: 55.
   Web of Science ®Google Scholar
• Higashide T, Ohkubo S, Sugiyama K. Long-term outcomes and prognostic factors of trabeculectomy following intraocular bevacizumab injection for neovascular glaucoma. PLoS One 2015; 10: e0135766.
   Web of Science ®Google Scholar
• Christakis PG, Kalenak JW, Tsai JC, et al. The Ahmed versus baerveldt study: five-year treatment outcomes. Ophthalmology 2016; 123: 2093–2102.
   PubMed Web of Science ®Google Scholar
• Bloom PA, Tsai JC, Sharma K, et al. “Cyclodiode”. Trans-scleral diode laser cyclophotocoagulation in the treatment of advanced refractory glaucoma. Ophthalmology 1997; 104: 1508–1519. discussion 1519-1520.
   PubMed Web of Science ®Google Scholar
• Yildirim N, Yalvac IS, Sahin A, et al. A comparative study between diode laser cyclophotocoagulation and the Ahmed glaucoma valve implant in neovascular glaucoma: a long-term follow-up. J Glaucoma 2009; 18: 192–196.
   PubMed Web of Science ®Google Scholar
• Schultz RO, Van Horn DL, Peters MA, et al. Diabetic keratopathy. Trans Am Ophthalmol Soc 1981; 79: 180–199.
   PubMedGoogle Scholar
• Bonini S, Rama P, Olzi D, et al. Neurotrophic keratitis. Eye (Lond). 2003;17:989–995.
   PubMed Web of Science ®Google Scholar
• Reid TW, Murphy CJ, Iwahashi CK, et al. Stimulation of epithelial cell growth by the neuropeptide substance P. J Cell Biochem 1993; 52: 476–485.
   PubMed Web of Science ®Google Scholar
• Tsubota K, Chiba K, Shimazaki J. Corneal epithelium in diabetic patients. Cornea 1991; 10: 156–160.
   PubMed Web of Science ®Google Scholar
• Lockwood A, Hope-Ross M, Chell P. Neurotrophic keratopathy and diabetes mellitus. Eye (Lond) 2006; 20: 837–839.
   PubMed Web of Science ®Google Scholar
• Deeks ED, Lamb YN. Cenegermin: a review in neurotrophic keratitis. Drugs 2020; 80: 489–494.
   PubMed Web of Science ®Google Scholar
• Vinik AI, Maser RE, Mitchell BD, et al. Diabetic autonomic neuropathy. Diabetes Care 2003; 26: 1553–1579.
   PubMed Web of Science ®Google Scholar
• Sudhakar P. Commentary: recognizing pupillary dysfunction in diabetic autonomic neuropathy. Indian J Ophthalmol 2019; 67: 1320–1321.
   Web of Science ®Google Scholar
• Kiziltoprak H, Tekin K, Inanc M, et al. Cataract in diabetes mellitus. World J Diabetes 2019; 10: 140–153.
   PubMed Web of Science ®Google Scholar
• Greco D, Gambina F, Pisciotta M, et al. Clinical characteristics and associated comorbidities in diabetic patients with cranial nerve palsies. J Endocrinol Invest 2012; 35: 146–149.
   Web of Science ®Google Scholar
• Al Kahtani ES, Khandekar R, Al-Rubeaan K, et al. Assessment of the prevalence and risk factors of ophthalmoplegia among diabetic patients in a large national diabetes registry cohort. BMC Ophthalmol 2016; 16: 118.
   Web of Science ®Google Scholar
• Moster ML. Neuro-ophthalmology of diabetes. Curr Opin Ophthalmol 1999; 10: 376–381.
   Google Scholar
• Saxena S, Mitchell P, Rochtchina E. Five-year incidence of cataract in older persons with diabetes and pre-diabetes. Ophthalmic Epidemiol 2004; 11: 271–277.
   PubMed Web of Science ®Google Scholar
• Klein BE, Klein R, Moss SE. Prevalence of cataracts in a population-based study of persons with diabetes mellitus. Ophthalmology 1985; 92: 1191–1196.
   PubMed Web of Science ®Google Scholar
• Ederer F, Hiller R, Taylor HR. Senile lens changes and diabetes in two population studies. Am J Ophthalmol 1981; 91: 381–395.
   PubMed Web of Science ®Google Scholar
• Klein BE, Klein R, Lee KE. Diabetes, cardiovascular disease, selected cardiovascular disease risk factors, and the 5-year incidence of age-related cataract and progression of lens opacities: the Beaver Dam Eye Study. Am J Ophthalmol 1998; 126: 782–790.
   PubMed Web of Science ®Google Scholar
• Uddin JM, Rubinstein T, Hamed-Azzam S. Phenotypes of thyroid eye disease. Ophthalmic Plast Reconstr Surg 2018; 34: S28–s33.
   Web of Science ®Google Scholar
• Nunery WR, Martin RT, Heinz GW, et al. The association of cigarette smoking with clinical subtypes of ophthalmic Graves’ disease. Ophthalmic Plast Reconstr Surg 1993; 9: 77–82.
   PubMed Web of Science ®Google Scholar
• Menconi F, Profilo MA, Leo M, et al. Spontaneous improvement of untreated mild Graves’ ophthalmopathy: rundle’s curve revisited. Thyroid 2014; 24: 60–66.
   PubMed Web of Science ®Google Scholar
• Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 2020; 382: 341–352.
   PubMed Web of Science ®Google Scholar
• Achtsidis V, Tentolouris N, Theodoropoulou S, et al. Dry eye in Graves ophthalmopathy: correlation with corneal hypoesthesia. Eur J Ophthalmol 2013; 23: 473–479.
   Web of Science ®Google Scholar
• Ismailova DS, Fedorov AA, Grusha YO. Ocular surface changes in thyroid eye disease. Orbit 2013; 32: 87–90.
   PubMedGoogle Scholar
• Selter JH, Gire AI, Sikder S. The relationship between Graves’ ophthalmopathy and dry eye syndrome. Clin Ophthalmol 2015; 9: 57–62.
   Web of Science ®Google Scholar
• Wei YH, Chen WL, Hu FR, et al. In vivo confocal microscopy of bulbar conjunctiva in patients with Graves’ ophthalmopathy. J Formos Med Assoc 2015; 114: 965–972.
   PubMed Web of Science ®Google Scholar
• Gilbard JP, Farris RL. Ocular surface drying and tear film osmolarity in thyroid eye disease. Acta Ophthalmol (Copenh) 1983; 61: 108–116.
   PubMed Web of Science ®Google Scholar
• Kishazi E, Dor M, Eperon S, et al. Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy. Sci Rep 2018; 8: 10792.
   PubMed Web of Science ®Google Scholar
• Choi W, Li Y, Ji YS, et al. Oxidative stress markers in tears of patients with Graves’ orbitopathy and their correlation with clinical activity score. BMC Ophthalmol 2018; 18: 303.
   Web of Science ®Google Scholar
• Huang D, Luo Q, Yang H, et al. Changes of lacrimal gland and tear inflammatory cytokines in thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci 2014; 55: 4935–4943.
   PubMed Web of Science ®Google Scholar
• Park J, Baek S. Dry eye syndrome in thyroid eye disease patients: the role of increased incomplete blinking and Meibomian gland loss. Acta Ophthalmol 2019; 97: e800–e806.
   PubMed Web of Science ®Google Scholar
• Wu LQ, Cheng JW, Cai JP, et al. Observation of corneal langerhans cells by in vivo confocal microscopy in thyroid-associated ophthalmopathy. Curr Eye Res 2016; 41: 927–932.
   PubMed Web of Science ®Google Scholar
• Lin IC, Lee CC, Liao SL. Assessing quality of life in Taiwanese patients with Graves’ ophthalmopathy. J Formos Med Assoc 2015; 114: 1047–1054.
   PubMed Web of Science ®Google Scholar
• Dolman PJ. Dysthyroid optic neuropathy: evaluation and management. J Endocrinol Invest 2021; 44: 421–429.
   Web of Science ®Google Scholar
• Chiou CA, Reshef ER, Freitag SK. Teprotumumab for the treatment of mild compressive optic neuropathy in thyroid eye disease: a report of two cases. Am J Ophthalmol Case Rep 2021; 22: 101075.
   Google Scholar
• Hwang CJ, Nichols EE, Chon BH, et al. Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab. Eur J Ophthalmol 2021; 1120672121991042.
   Web of Science ®Google Scholar
• Lyons DE. Postural changes in IOP in dysthyroid exophthalmos. Trans Ophthalmol Soc U K 1971; 91: 799–803.
   PubMedGoogle Scholar
• Behrouzi Z, Rabei HM, Azizi F, et al. Prevalence of open-angle glaucoma, glaucoma suspect, and ocular hypertension in thyroid-related immune orbitopathy. J Glaucoma 2007; 16: 358–362.
   PubMed Web of Science ®Google Scholar
• Skalicky SE, Borovik AM, Masselos K, et al. Prevalence of open-angle glaucoma, glaucoma suspect, and ocular hypertension in thyroid-related immune orbitopathy. J Glaucoma 2008; 17: 249. author reply 249-250.
   Web of Science ®Google Scholar
• Goldberg I. Thyroid eye disease and glaucoma. J Glaucoma 2003; 12: 494–496.
   PubMed Web of Science ®Google Scholar
• Mehran NA, Sinha S, Razeghinejad R. New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. Eye (Lond) 2020; 34: 72–88.
   Web of Science ®Google Scholar
• Kalmann R, Mourits MP. Prevalence and management of elevated intraocular pressure in patients with Graves’ orbitopathy. Br J Ophthalmol 1998; 82: 754–757.
   PubMed Web of Science ®Google Scholar
• Firschein HE. Lenticular effects of parathyroid hormone. Invest Ophthalmol Vis Sci 1962; 1: 788–791.
   Google Scholar
• Abate EG, Clarke BL. Review of hypoparathyroidism. Front Endocrinol (Lausanne) 2016; 7: 172.
   PubMed Web of Science ®Google Scholar
• Goyal J, Kang J, Gupta R, et al. Bilateral papilledema in hypocalcemia. Official Sci J Delhi Ophthalmol Soc 2012; 23: 127–130.
   Google Scholar
• Gradisnik P. Hypoparathyroidism should always be checked in papilledema. J Neurosci Rural Pract 2017; 8: 329.
   PubMed Web of Science ®Google Scholar
• Arshad MF, Karim R, Paling D, et al. Optic neuritis as presenting primary hypoparathyroidism. BMJ Case Reports CP 2018; 11: e227032.
   Google Scholar
• Finny P, Jacob JJ, Thomas N. Primary hyperparathyroidism presenting as redness of eyes. Eur J Intern Med 2007; 18: 608.
   Web of Science ®Google Scholar
• Eom Y, Han JY, Kang SY, et al. Calcium hydroxyapatite crystals in the anterior chamber of the eye in a patient with renal hyperparathyroidism. Cornea 2013; 32: 1502–1504.
   Web of Science ®Google Scholar
• Tieger MG, Hedges TR 3rd, Ho J, et al. Ganglion cell complex loss in chiasmal compression by brain tumors. J Neuroophthalmol 2017; 37: 7–12.
   PubMed Web of Science ®Google Scholar
• Freda PU, Post KD. Differential diagnosis of sellar masses. Endocrinol Metab Clin North Am 1999; 28: 81–117. vi.
   PubMed Web of Science ®Google Scholar
• Connor SEJ, Penney CC. MRI in the differential diagnosis of a sellar mass. Clin Radiol 2003; 58: 20–31.
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Ogawa Y, Tominaga T. Retinal nerve fiber layer thickness measurement for predicting visual outcome after transsphenoidal surgery: optic disc atrophy is not the deciding indicator. World Neurosurg 2019; 127: e427–e435.
   Web of Science ®Google Scholar
• Mortini P, Losa M, Barzaghi R, et al. Results of transsphenoidal surgery in a large series of patients with pituitary adenoma. Neurosurgery 2005; 56: 1222–1233. discussion 1233.
   PubMed Web of Science ®Google Scholar
• Briet C, Salenave S, Bonneville JF, et al. Pituitary apoplexy. Endocr Rev 2015; 36: 622–645.
   PubMed Web of Science ®Google Scholar
• Chopra R, Chander A, Jacob J. The eye as a window to rare endocrine disorders. Indian J Endocrinol Metab 2012; 16: 331–338.
   Google Scholar
• Bouzas EA, Scott MH, Mastorakos G, et al. Central serous chorioretinopathy in endogenous hypercortisolism. Arch Ophthalmol 1993; 111: 1229–1233.
   PubMed Web of Science ®Google Scholar
• van Dijk EH, Dijkman G, Biermasz NR, et al. Chronic central serous chorioretinopathy as a presenting symptom of Cushing syndrome. Eur J Ophthalmol 2016; 26: 442–448.
   Web of Science ®Google Scholar
• Aygun N, Uludag M. Pheochromocytoma and Paraganglioma: from clinical findings to diagnosis. Sisli Etfal Hastan Tip Bul 2020; 54: 271–280.
   Web of Science ®Google Scholar
• Jayarajah U, Herath KB, Fernando MH, et al. Phaeochromocytoma of the urinary bladder presenting with malignant hypertension and hypertensive retinopathy. Asian J Urol 2020; 7: 70–72.
   Web of Science ®Google Scholar